Vaccines usually require years of research and testing before they reach the masses, but scientists in Russia have reported that the Covid-19 vaccine shows some positive results in early-stage trials.
The Lancet medical journal reports that Sputnik-V has passed two trials involving 76 participants.
The result was that 100% of participants developed antibodies against the new corona virus without severe side effects.
The journal further states that large long-term trials including placebo comparisons and further monitoring are needed.
This was done to determine the long-term safety and effectiveness of vaccines to prevent COVID-19 infection.
Russia licensed the two-shot jab vaccine for domestic use in August, although it has published no data or large-scale trials.
The next steps for the Sputnik-V vaccine will enter into robust advanced trials.
The trial requires 40,000 participants.
